Video Lectures
State-of-the-industry video lectures by leading urology experts
Latest Videos

SAN FRANCISCO, CA USA ( - Dr. Timur Mitin presented an abstract comparing outcomes in complete and near-complete responses (CR and nCR) in bladder preservation protocols.

Previous randomized studies in bladder preservation protocols necessitated a radical cystectomy for patients with residual disease after induction therapy. However, pathological analyses of these specimens showed that many of the patients had minimal residual disease. This prompted the RTOG to determine if such minimal residual disease can be safely managed without cystectomy.

gucancerssympalt thumbDr. Mitin presented the data from RTOG 9906 which was a single-arm prospective trial of bladder preservation with twice daily radiation and radio-sensitizing chemotherapy, and also data from RTOG 0233 which was a randomized controlled trial assessing two different chemotherapy regimens, in addition to radiation. He compared the outcomes of CR (n=101) and nCR (n=18) patients and showed that there was no significant difference in recurrence, muscle-invasive recurrence, salvage cystectomy rates, or overall survival. This suggests that patients with non-muscle invasive disease, after bladder preservation protocols, may be safely observed and managed endoscopically.

Highlights of a presentation by Timur Mitin, MD, PhD at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

Massachusetts General Hospital, Boston, MA USA

Written by Phillip Abbosh, MD, PhD, medical writer for

View Full 2014 GU Cancers Symposium Coverage


Upcoming urology industry events
July 9-12, 2018 / Tan Tock Seng Hospital
Urology Residents' Course Singapore 2018
July 13-14, 2018 / Manchester Grand Hyatt San Diego
Best of ASCO 2018 - San Diego
Print publications focusing on urological cancer treatments through original commentary & articles
Everyday Urology Volume 2 Issue 4

Everyday Urology™ - Oncology Insights

From the Editor

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor